Enanta Pharmaceuticals
ENTA
$12.47
Share price
3.92%
Change (1 day)
-49.62%
Change (1 year)
Categories
Enanta Pharmaceuticals (ENTA) - P/B ratio
P/B ratio as of June 2024 : 1.53
According to Enanta Pharmaceuticals
's latest financial reports the company has a price-to-book ratio of 1.53.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Enanta Pharmaceuticals - P/B ratio (from 2013 to 2024)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2024-12-31 | N/A | -100% |
| 2023-12-31 | 1.03 | -67.89% |
| 2022-12-31 | 3.22 | -19.38% |
| 2021-12-31 | 3.99 | 113.3% |
| 2020-12-31 | 1.87 | -26.3% |
| 2019-12-31 | 2.54 | -21.32% |
| 2018-12-31 | 3.23 | -8.74% |
| 2017-12-31 | 3.53 | 48.58% |
| 2016-12-31 | 2.38 | 1.29% |
| 2015-12-31 | 2.35 | -51.94% |
| 2014-12-31 | 4.89 | 5.25% |
| 2013-12-31 | 4.64 | |
| 2012-12-31 | N/A | |
| 2011-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 4.99 | 226.37% | 🇺🇸 USA |
 Novartis NVS | 5.17 | 237.80% | 🇨🇭 Switzerland |
 AbbVie ABBV | 34.3 | 2,141.94% | 🇺🇸 USA |
 Vertex Pharmaceuticals VRTX | 6.16 | 302.91% | 🇺🇸 USA |
 Merck MRK | 7.89 | 415.58% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 4.93 | 222.26% | 🇺🇸 USA |